Evidence map›Paper›PMID 33888093›Full record

ArticleBMC musculoskeletal disorders2021

The validity of the claims-based definition of rheumatoid arthritis evaluated in 64 hospitals in Japan.

Kiyoshi Kubota, Masaki Yoshizawa, Satoru Takahashi, Yoshiaki Fujimura, Hiroko Nomura, Hitoshi Kohsaka

Open access · goldAbstract read
In one paragraph

Article in BMC musculoskeletal disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Kiyoshi KubotaNPO Drug Safety Research Unit Japan, 6-2-9-2F, Soto-Kanda, Chiyoda-ku, Tokyo, 101-0021, Japan. kubota@dsrujp.org.
Masaki YoshizawaDepartment of Rheumatology, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.
Satoru TakahashiTokushukai General Incorporated Association Tokyo Headquarters, Chiyoda-ku, Tokyo, Japan.
Yoshiaki FujimuraTokushukai Information System, Inc., Osaka-shi, Osaka, Japan.
Hiroko NomuraTokushukai General Incorporated Association Osaka Headquarters, Osaka-shi, Osaka, Japan.
Hitoshi KohsakaRheumatology Center, Chiba-Nishi General Hospital, Matsudo, Chiba, Japan.
Chiba-Nishi General Hospital · JPFood and Drug Safety Center · JPFukuoka Tokushukai Hospital · JPShonan Kamakura General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn administrative database covering a whole population such as the national database in Japan may be used to estimate the nationwide prevalence of diseases including rheumatoid arthritis (RA) when a well-validated definition of the disease is available. In Japan, the record linkage between the administrative database and medical charts in hospitals is strictly prohibited. A "hospital-based" validation study is one of few possible validation studies where claims kept inside the study hospital are rearranged into the database structure.

methodsWe selected random samples of 19,734 patients from approximately 1.6 million patients who received medical care between February 2018 and January 2019 in one of the 64 hospitals of the Tokushukai Medical Group. We excluded patients whose observation period was less than 365 days and identified 334 patients who met the definition of "possible cases of RA" whose medical charts were then independently evaluated by two rheumatologists. In a sensitivity analysis, we assessed bias due to misclassifying some patients with RA who did not meet the definition of "possible cases of RA" as a patient with no RA.

resultsThe kappa coefficient between the two rheumatologists was 0.80. The prevalence of RA in the study population was estimated to be 0.56%. We found that [condition code of RA] and ([any disease-modifying antirheumatic drug] or [oral corticosteroid with no systemic autoimmune diseases (other than RA) and no polymyalgia rheumatica]) had a relatively high sensitivity (approximately 73%) and a high positive predictive value (approximately 80%). In a sensitivity analysis, we found that when some patients with RA who did not meet the definition of "possible cases of RA" were misclassified as a patient with no RA, then this would lead to underestimation of the prevalence of the definition-positive patients and the adjusted prevalence.

conclusionsWe recommend using the claims-based definition of RA (found in the current validation study) to estimate the prevalence of RA in Japan. We also suggest estimating the adjusted prevalence using the quantitative bias analysis method, since the prevalence of the disease in the "hospital-based" validation study is different from that in the administrative database.

trial registrationThe current study is not a clinical trial and hence not subject to trial registration.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidHospitalsHumansJapanRheumatologistsAntirheumatic AgentsBias analysisNegative predictive valuePositive predictive valueRheumatoid arthritisSensitivitySpecificityValidation study

Identifiers

PMID33888093
PMCPMC8063301
OpenAlexW3156156796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.